Shenzhen's 'Huiminbao' covers all 19 drugs listed in national commercial-insurance drug list

The 19 innovative medicines included in China’s inaugural commercial insurance catalog that was recently released, have been covered in the 2025 benefits package of Shenzhen’s local inclusive commercial health insurance scheme, “Shenzhen Huiminbao.”

The national catalog is designed as a supplement to basic medical insurance, prioritizing drugs with high levels of innovation, substantial clinical value and clear patient benefit that fall outside the scope of standard public coverage. The first edition includes treatments across several critical areas — notably oncology therapies such as CAR-T, medicines for rare diseases including treatments for Gaucher disease, and drugs for neurodegenerative conditions that have drawn wide social attention, such as Alzheimer’s therapies.

Under the arrangement, all Shenzhen residents insured by Shenzhen Huiminbao who use any of the 19 listed innovative medicines and meet the scheme’s claims criteria will be eligible for reimbursement, reducing out-of-pocket spending and improving practical access to cutting-edge treatments. Officials said the move aims to remove the “last-mile” barrier that often prevents patients from obtaining high-cost innovative drugs even after they gain regulatory approval.